Medplus Health Services Limited Business Intelligence Report

Latest Annual Report • Financial Analysis • Management Commentary • Earnings Summary • Official Filings
Official Annual + Quarterly Filings · AI Business Intelligence
NSE: MEDPLUS
Sector: Consumer Services
Industry: Pharmacy Retail
Source: NSE / BSE
Last Updated: 21 Jul 2026
Business Intelligence Report Verdict
High
Outlook: Positive

Quality Scores

Business Compounding
82/100
Compounder
81/100
Management
80/100
Governance
68/100
Cash Flow
78/100

Latest Quarterly Earnings Summary

No quarterly summary available yet.

AI Summary

Medplus Health Services is India's second-largest pharmacy retailer, demonstrating a robust expansion strategy with approximately 4,930 stores operating across 13 states as of late FY26. The business exhibits high revenue visibility through its strategic cluster-based expansion, which has fueled a 10-year sales CAGR of 15% and a more aggressive 10-year profit CAGR of 37%. While the business model is inherently capital-intensive, the company has successfully transitioned into a phase of significant operational leverage, as evidenced by improving OPM from 2% in FY15 to 9% in FY26. Management's…

Key Changes in FY2026

MedPlus has evolved from a regional pharmacy player into India’s 2nd largest pharmacy retailer with a presence in 750 cities. The business has successfully transitioned from a pure-play retail model to a sophisticated omni-channel platform incorporating diagnostics and private labels. Over the last decade, sales have grown from INR 1,368 Cr in 2015 to a projected INR 6,892 Cr in 2026, representing a 15% CAGR. Recent strategic pivots include a heavier push into Tier-2 and Tier-3 cities, which accounted for over 50% of recent store additions. The introduction of diagnostics and the increasing share of private label products (though specific percentages are behind premium locks) indicate a move toward higher-margin vertical integration.

Management Commentary

Management execution has been largely consistent with the stated objective of becoming a dominant pharmacy player in Southern and Western India. Communication in earnings calls provides clarity on store economics, relocation strategies, and the competitive landscape from 1mg and Apollo. However, the high promoter pledge of 60.7% is a noticeable governance concern that impacts the 'Management Quality' score despite strong operational performance. Pay scales appear aligned with company size, but the lack of dividend reflects a growth-at-all-costs mindset that may eventually need to shift toward shareholder payouts. The transition to Q2 FY26 figures shows a management team capable of navigating inflationary pressures in rentals and personnel costs while maintaining margin expansion.

Financial Highlights

The financial trajectory of Medplus indicates a disciplined transition from a high-growth, low-margin startup phase to a mature profitable entity. Operating margins have consistently expanded from 6-7% in the FY22-24 period to reaching 9% in FY26, suggesting that store-level efficiencies are beginning to outpace corporate overheads. Revenue growth has remained steady at 12-18% across multiple timeframes, providing a reliable baseline for compounding. However, the company maintains a high level of borrowings (₹1,424 Cr in FY26) to fund its aggressive store rollout, resulting in an interest coverage ratio that requires continuous monitoring. Return on Equity (ROE) has improved to 12% in the latest fiscal, though the 3-year average remains lower at 8% due to the heavy capital base required…

Major Opportunities

  • Second largest pharmacy retailer in India
  • Consistent double-digit revenue growth
  • Improving Operating Profit Margins (OPM)

Major Risks

  • High promoter pledge of 60.7%
  • No dividend payout despite repeated profitability
  • Regulatory risk from frequent drug license suspensions

About Medplus Health Services Limited's Annual Report & Financial Performance

The latest Medplus Health Services Limited annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.

What this Medplus Health Services Limited research covers

  • Fundamental & business analysis
  • Financial statements & performance
  • Management commentary & discussion
  • Corporate governance & auditor report
  • Cash flow analysis & capital allocation
  • Valuation analysis & business quality
  • Growth analysis & competitive position
  • Risk, SWOT & moat analysis
  • Quarterly earnings & conference-call summary
  • Sector, industry & peer comparison
  • Latest official company filings
  • Business outlook & long-term growth

Medplus Health Services Limited — Frequently Asked Questions

Explore more Medplus Health Services Limited research

AI Top Insights — Premium

Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.